Clinical biomarkers are critical in contemporary oncology, informing diagnosis, prognosis, and individualized treatment approaches. The session "Clinical Biomarkers" is dedicated to the discovery, validation, and utilization of molecular, cellular, and imaging biomarkers for cancer management.".
Biomarkers may provide evidence of cancer's presence, forecast disease progression, track response to treatment, and identify recurrence. Examples include genetic mutations, protein expression profiles, circulating tumor DNA, RNA signatures, and metabolic markers. The incorporation of biomarker information into clinical decision-making allows clinicians to match therapies to the unique patient, enhancing efficacy while minimizing unnecessary toxicity.
The session covers new biomarker technologies, such as liquid biopsy, high-throughput sequencing, proteomics, and next-generation imaging biomarkers. These technologies provide real-time tracking, early therapy resistance detection, and actionable targets identification for precision oncology. Biomarker-guided trials are also driving targeted therapies and immunotherapy development at a faster rate.
Participants will learn about biomarker discovery, clinical validation, and translational applications in patient care. This session focuses on how clinical biomarkers are revolutionizing the management of cancer by providing personalized treatment, predicting outcome, and improving therapeutic precision, leading to better survival and quality of life for cancer patients.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
